0001104659-24-000859.txt : 20240103
0001104659-24-000859.hdr.sgml : 20240103
20240103162943
ACCESSION NUMBER: 0001104659-24-000859
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240102
FILED AS OF DATE: 20240103
DATE AS OF CHANGE: 20240103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fortress Biotech, Inc.
CENTRAL INDEX KEY: 0001429260
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38191
FILM NUMBER: 24506983
BUSINESS ADDRESS:
STREET 1: 1111 KANE CONCOURSE
STREET 2: SUITE 301
CITY: BAY HARBOR ISLANDS
STATE: FL
ZIP: 33154
BUSINESS PHONE: 781-652-4500
MAIL ADDRESS:
STREET 1: 1111 KANE CONCOURSE
STREET 2: SUITE 301
CITY: BAY HARBOR ISLANDS
STATE: FL
ZIP: 33154
FORMER NAME:
FORMER CONFORMED NAME: CORONADO BIOSCIENCES INC
DATE OF NAME CHANGE: 20080310
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MUSTANG BIO, INC.
CENTRAL INDEX KEY: 0001680048
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 473828760
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 377 PLANTATION STREET
CITY: WORCESTER
STATE: MA
ZIP: 01605
BUSINESS PHONE: 7816524500
MAIL ADDRESS:
STREET 1: 377 PLANTATION STREET
CITY: WORCESTER
STATE: MA
ZIP: 01605
4
1
tm241755-3_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-01-02
0
0001680048
MUSTANG BIO, INC.
MBIO
0001429260
Fortress Biotech, Inc.
1111 KANE CONCOURSE SUITE 301
BAY HARBOR ISLANDS
FL
33154
0
0
1
0
0
COMMON STOCK, PAR VALUE $0.0001
2024-01-02
4
A
0
419092
0.00
A
1927800
D
Effective April 3, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split.
The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. 66,003 shares were granted by the Issuer to the Reporting Person following the closing of equity financings.
The Reporting Person is entitled to an annual dividend on its Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. 353,089 shares were granted by the Issuer to the Reporting Person for the 2023 annual dividend.
/s/ Samuel Berry, General Counsel and Authorized Agent
2024-01-03